Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer

To identify clinical benefits of dose escalation in accelerated hyperfractionated radiotherapy (AH-RT) for stage III non-small-cell lung cancer (NSCLC) using propensity score-matched (PSM) analysis. Our study retrospectively examined 294 patients undergoing definitive radiotherapy [131 patients, con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2018-10, Vol.38 (10), p.5951-5958
Hauptverfasser: Wada, Kentaro, Kishi, Noriko, Kanayama, Naoyuki, Hirata, Takero, Morimoto, Masahiro, Konishi, Koji, Imamura, Fumio, Teshima, Teruki, Ogawa, Kazuhiko
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Cancer
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - radiotherapy
Confidence intervals
Dose Fractionation
Female
Follow-Up Studies
Health risk assessment
Humans
Lung cancer
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - radiotherapy
Male
Middle Aged
Neoplasm Staging
Non-small cell lung carcinoma
Patients
Propensity Score
Radiation
Radiation dosage
Radiation therapy
Retrospective Studies
Survival
Survival Rate
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To identify clinical benefits of dose escalation in accelerated hyperfractionated radiotherapy (AH-RT) for stage III non-small-cell lung cancer (NSCLC) using propensity score-matched (PSM) analysis. Our study retrospectively examined 294 patients undergoing definitive radiotherapy [131 patients, conventional once-daily radiotherapy (OD-RT); and 163, AH-RT] who were followed-up for a median of 40.4 months. The impact of overall survival (OS), progression-free survival (PFS), and locoregional control (LRC) was investigated. Pre-PSM, the median OS, PFS, and LRC durations were 23.1 vs. 39.9 (p=0.03), 8.9 vs. 13.5 (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12941